公开(公告)号：WO2022047241A1

公开(公告)日：2022-03-03

申请号：PCT/US2021/048072

申请日：2021-08-27

Applicant: BEREN THERAPEUTICS P.B.C.

Inventor： KERWIN, Diana ,  CAMM, Jason

IPC: A61K31/724 ,  A61K9/08 ,  A61K9/10 ,  A61P3/06 ,  A61P9/10

Abstract: Disclosed herein are methods for reducing an amount of and/or a size of, and/or changing the shape of circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of treating cholesterol crystal embolization (CCE) and/or a symptom thereof in an individual. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.

公开(公告)号：WO2022178318A1

公开(公告)日：2022-08-25

申请号：PCT/US2022/017090

申请日：2022-02-18

Applicant: BEREN THERAPEUTICS P.B.C.

Inventor： KERWIN, Diana ,  CAMM, Jason ,  DUCKERS, Henricus

IPC: A61K31/70 ,  A61K31/7088 ,  A61K31/713

Abstract: Disclosed herein are methods alleviating or reducing inflammation and/or oxidative stress induced by oxidized LDL, reducing an amount (e.g., concentration) total cholesterol, reducing accumulation of total LDL, reducing an amount (e.g., concentration) of and/or a size (e.g., average size, maximum size) of, and/or changing the shape of circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of treating familial hypercholesterolemia, reducing statin, cholesterol uptake inhibitor or PCSK9 inhibitor treatment, or reducing a frequency of, or delaying plasmapheresis treatment of a subject diagnosed with or suspected to have familial hypercholesterolemia. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.

公开(公告)号：WO2022047249A1

公开(公告)日：2022-03-03

申请号：PCT/US2021/048084

申请日：2021-08-27

Applicant: BEREN THERAPEUTICS P.B.C.

Inventor： KERWIN, Diana ,  CAMM, Jason

IPC: A61K31/724 ,  A61K9/08 ,  A61P9/10 ,  A61P3/06

Abstract: Disclosed herein are methods treating atherosclerosis and/or atherosclerotic cardiovascular disease (e.g., coronary artery disease (CAD), peripheral artery disease (PAD), peripheral vascular disease (PVD), stroke, chronic kidney disease (CKD) caused by atherosclerosis, end-stage kidney disease (ESKD) caused by atherosclerosis, acute kidney failure caused by atherosclerosis, atherosclerotic renovascular disease (ARVD), renal artery stenosis, aortic aneurysm, idiopathic peripheral atrial hypertension, erectile dysfunction, intermittent claudication, post-surgical or iatrogenic arterial disease) by administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the subject. In some cases, the therapeutically effective amount is an amount sufficient to increase a circulating and/or systemic level of one or more sterol or oxysterol in the subject compared to a baseline, an amount effective to increase a level of ABCA1 and/or ABCG1 in the subject compared to a baseline, an amount effective to increase a level of plasma cholesterol crystal dissolution capacity in the subject compared to a baseline, or any combination thereof.

公开(公告)号：WO2022047244A1

公开(公告)日：2022-03-03

申请号：PCT/US2021/048075

申请日：2021-08-27

Applicant: BEREN THERAPEUTICS P.B.C.

Inventor： KERWIN, Diana ,  CAMM, Jason

IPC: A61K31/724 ,  A61K9/08 ,  A61K9/10 ,  A61P3/06 ,  A61P9/10

Abstract: Disclosed herein are methods for preventing or reducing the risk of developing, and/or preventing or reducing the risk of an increase in an amount of and/or a size of, and/or changing the shape of, circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of preventing or reducing the risk of cholesterol crystal embolization (CCE) and/or a symptom thereof in an individual. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.